AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR^L858R/T790M in non-small cell lung cancer cells

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Osimertinib 100%
• Epidermal Growth Factor Receptor 60%
• Neoplasm 20%
• Tumor Regression 10%
• Epidermal Growth Factor Receptor Kinase Inhibitor 10%
• Proteasome 10%
• Receptor Protein 10%
• Benzyloxycarbonylleucylleucylleucinal 10%

Immunology and Microbiology

• Cancer Cell 100%
• Epidermal Growth Factor 100%
• Xenograft 28%
• Programmed Cell Death 14%
• Tyrosine 14%
• Proteasome 14%
• Wild Type 14%
• Cell Growth 14%
• Cell Cycle 14%

Medicine and Dentistry

• Benzyloxycarbonylleucylleucylleucinal 10%